Section Arrow
LITS.NASDAQ
- Lite Strategy Inc.
Quotes are at least 15-min delayed:2026/07/07 14:16 EDT
Regular Hours
Last
 0.981
+0.0053 (+0.54%)
Day High 
0.9961 
Prev. Close
0.9757 
1-M High
1.01 
Volume 
146.36K 
Bid
0.981
Ask
0.9899
Day Low
0.94 
Open
0.98 
1-M Low
0.6888 
Market Cap 
32.34M 
Currency 美元 
P/E -- 
%Yield 57 
10-SMA 0.91 
20-SMA 0.85 
50-SMA
52-W High
52-W Low 0.6888 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.08/-19.36
Enterprise Value
32.34M
Balance Sheet
Book Value Per Share
1.67
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
40.70M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CRNXCrinetics Pharmaceuticals83.5+41.47+98.67%-- 
TVRDTvardi Therapeutics Inc2.99+0.98+48.76%-- 
RXRXRecursion Pharmaceuticals3.92-0.04-1.01%-- 
TOVXTheriva Biologics Inc0.23165-0.02165-8.55%-- 
VANIVivani Medical1.335+0.035+2.69%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily,selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.